Compare Novo Nordisk A/S (NVO) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Phillips 66 — how do they compare? Novo Nordisk A/S trades at $46.23 (market cap $207.85B), while Phillips 66 trades at $226.22 (market cap $89.52B). The key difference: Novo Nordisk A/S is far larger — about 2.3× Phillips 66's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | PSX | |
|---|---|---|
Market Cap | $207.85B | $89.52B |
Sector | Health | Energy |
52-Week High | $63.98 | $224.36 |
52-Week Low | $35.29 | $120.04 |
Enterprise Value | $222.55B | $105.99B |
Dividend Yield | 3.81% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Phillips 66 (PSX) trades at $225.04, up 4.41% today, reflecting strong momentum after Q2 2026 earnings beat. The stock shows bullish technical signals with support near $220 and resistance at $227. Fundamentally, the company reported robust Q2 EPS of $9.41, exceeding estimates, driven by high refining margins and operational efficiency. Recent news highlights a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream assets.
Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a price target of $221.92. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical factors affecting energy markets. The stock's valuation metrics, like P/E of 12.81, suggest room for upside if earnings trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
